Zobrazeno 1 - 10
of 206
pro vyhledávání: '"C. Fernández-López"'
Autor:
Javier Loricera, Santos Castañeda, Clara Moriano, Javier Narváez, Vicente Aldasoro, Olga Maiz, Rafael Melero, Ignacio Villa, Paloma Vela, Susana Romero-Yuste, José L. Callejas, Eugenio de Miguel, Eva Galíndez-Agirregoikoa, Francisca Sivera, Jesús C. Fernández-López, Carles Galisteo, Iván Ferraz-Amaro, Julio Sánchez-Martín, Lara Sánchez-Bilbao, Mónica Calderón-Goercke, Alfonso Casado, José L. Hernández, Miguel A. González-Gay, Ricardo Blanco
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 14 (2022)
Background: Visual involvement is the most feared complication of giant cell arteritis (GCA). Information on the efficacy of tocilizumab (TCZ) for this complication is scarce and controversial. Objective: We assessed a wide series of GCA treated with
Externí odkaz:
https://doaj.org/article/c13a8f0e153840678d33b671e30cf05b
Autor:
Sandra L. Romero-Cordoba, Ivan Salido-Guadarrama, Rosa Rebollar-Vega, Veronica Bautista-Piña, Carlos Dominguez-Reyes, Alberto Tenorio-Torres, Felipe Villegas-Carlos, Juan C. Fernández-López, Laura Uribe-Figueroa, Luis Alfaro-Ruiz, Alfredo Hidalgo-Miranda
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-19 (2021)
Cancers in different populations have been shown to be genetically distinct. Here, the authors sequence breast cancers from Mexican-Hispanic patients and find that these patients have a higher percentage of Akt1 mutations compared to Caucasian and As
Externí odkaz:
https://doaj.org/article/ee18d53057ea47c8996ebd5a4ca3bc1a
Autor:
Diana Prieto-Peña, Pilar Bernabeu, Paloma Vela, Javier Narváez, Jesús C. Fernández-López, Mercedes Freire-González, Beatriz González-Álvarez, Roser Solans-Laqué, José L. Callejas Rubio, Norberto Ortego, Carlos Fernández-Díaz, Esteban Rubio, Salvador García-Morillo, Mauricio Minguez, Cristina Fernández-Carballido, Eugenio de Miguel, Sheila Melchor, Eva Salgado, Beatriz Bravo, Susana Romero-Yuste, Juan Salvatierra, Cristina Hidalgo, Sara Manrique, Carlos Romero-Gómez, Patricia Moya, Noelia Álvarez-Rivas, Javier Mendizabal, Francisco Ortiz-Sanjuán, Iván Pérez de Pedro, José L. Alonso-Valdivielso, Laura Perez-Sanchez, Rosa Roldán, Nagore Fernandez-Llanio, Ricardo Gómez de la Torre, Silvia Suarez, María Jesús Montesa Cabrera, Mónica Delgado Sánchez, Javier Loricera, Belén Atienza-Mateo, Santos Castañeda, Miguel A. González-Gay, Ricardo Blanco
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu’s arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The ou
Externí odkaz:
https://doaj.org/article/d3daa2f8a9974d32bf3007562457a783
Autor:
E Ambrocio-Ortiz, G Pérez-Rubio, A Ramírez-Venegas, R D J Hernández-Zenteno, J C Fernández-López, M E Ramírez-Díaz, F Cruz-Vicente, M D L Martínez-Gómez, J Pérez-Ramos, R Falfán-Valencia
Publikováno v:
03.01 - Molecular pathology and functional genomics.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Edith A Fernández-Figueroa, Iván Imaz-Rosshandler, Juan E Castillo-Fernández, Haydee Miranda-Ortíz, Juan C Fernández-López, Ingeborg Becker, Claudia Rangel-Escareño
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 10, Iss 3, p e0004570 (2016)
An important NK-cell inhibition with reduced TNF-α, IFN-γ and TLR2 expression had previously been identified in patients with diffuse cutaneous leishmaniasis (DCL) infected with Leishmania mexicana. In an attempt to pinpoint alterations in the sign
Externí odkaz:
https://doaj.org/article/2edf093174524b4aa7963486a47de8ea
Autor:
J. Sanchez-Martin, J. Loricera, C. Moriano, S. Castañeda, J. Narváez, V. Aldasoro, O. Maiz, R. Melero, I. Villa-Blanco, P. Vela-Casasempere, S. Romero-Yuste, J. L. Callejas-Rubio, E. De Miguel, E. Galíndez-Agirregoikoa, F. Sivera, C. Fernández-López, C. Galisteo, I. Ferraz-Amaro, L. Sanchez-Bilbao, M. Calderón-Goercke, J. L. Hernández Hernández, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:698-699
BackgroundTocilizumab (TCZ) is the only biologic drug approved in giant cell arteritis (GCA), based in two clinical trials (CT) (1,2). CT included selected patients who may differ from those of clinical practice (CP). A high proportion of GCA patient
Autor:
L. Sanchez-Bilbao, J. Loricera, R. Melero, S. Castañeda, C. Moriano, I. Ferraz-Amaro, J. Narváez, V. Aldasoro, O. Maiz, I. Villa-Blanco, P. Vela-Casasempere, S. Romero-Yuste, J. L. Callejas-Rubio, E. De Miguel, E. Galíndez-Agirregoikoa, F. Sivera, C. Fernández-López, C. Galisteo, J. Sanchez-Martin, M. Calderón-Goercke, J. L. Hernández, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:689-690
BackgroundLarge vessel involvement in Giant Cell Arteritis (GCA), especially the aorta and/or its main branches, is frequent. Tocilizumab (TCZ) has shown efficacy and safety in GCA and other large-vessel vasculitis (1-4).ObjectivesTo assess the effic
Autor:
D. Prieto-Peña, J. Loricera, S. Castañeda, C. Moriano, P. Bernabéu, P. Vela-Casasempere, J. Narváez, V. Aldasoro, O. Maíz, C. Fernández-López, M. Freire González, R. Melero, I. Villa-Blanco, B. González-Alvarez, R. Solans-Laqué, J. L. Callejas-Rubio, C. Fernández-Díaz, E. Rubio Romero, S. García Morillo, M. Minguez, C. Fernández-Carballido, E. De Miguel, J. Sanchez-Martin, E. Fernández, S. Melchor, E. Salgado-Pérez, B. Bravo, S. Romero-Yuste, E. Galíndez-Agirregoikoa, F. Sivera, I. Ferraz-Amaro, C. Hidalgo, C. Romero-Gómez, C. Galisteo, P. Moya, N. Alvarez-Rivas, J. Mendizabal, J. C. Nieto González, J. R. De Dios, J. L. Andreu, I. Pérez de Pedro, M. Revenga, J. L. Alonso Valdivieso, R. M. Rosa, I. De la Morena, N. Fernández-Llanio, E. Labrador, J. A. Roman-Ivorra, F. Ortiz-Sanjuán, A. García-Valle, A. Gallego, C. Iñiguez, N. Garrido-Puñal, R. De la Torre, R. López-González, P. Collado, E. Raya, F. Navarro, A. J. Mas, C. Ordás, M. D. Boquet, M. L. Velloso Feijoo, C. Campos Fernández, I. Rúa-Figueroa, A. Conesa, S. Manrique Arija, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:691-692
BackgroundTocilizumab (TCZ) has shown to be effective for large vessel vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK) (1-5). However, LVV-GCA and TAK show different demographic and clinical features that may influence on
Autor:
J. Sanchez-Martin, J. Loricera, S. Castañeda, C. Moriano, J. Narváez, V. Aldasoro, O. Maiz, R. Melero, I. Villa-Blanco, P. Vela-Casasempere, S. Romero-Yuste, J. L. Callejas-Rubio, E. De Miguel, E. Galíndez-Agirregoikoa, F. Sivera, C. Fernández-López, C. Galisteo, I. Ferraz-Amaro, L. Sanchez-Bilbao, M. Calderón-Goercke, J. L. Hernández Hernández, M. A. González-Gay, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:1789-1790
BackgroundPositron emission tomography (PET) is one of the tools available for the diagnosis of extracranial large-vessel vasculitis (1-5). Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitis (LVV) including GCA. However, the improvement